US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS

228.14

-10.7000-4.48%

Post-market: 228.140.00000.00%17:22 EDT

Volume:575.67K

Turnover:132.52M

Market Cap:24.58B

PE:-37.25

High:236.18

Open:235.00

Low:227.69

Close:238.84

Loading ...

Overview Company News Filings

TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy

BofA Securities Upgrades BeiGene to Buy, Price Target is $320

MT Newswires Live

Nomura Adjusts BeiGene Price Target to $347.02 From $316.65, Maintains Buy Rating

MT Newswires Live

Beigene Ltd : Bofa Global Research Raises to Buy From Neutral; Raises Price Objective to $320 From $207

THOMSON REUTERS

BeiGene upgraded to Buy from Neutral at BofA

Analysts’ Opinions Are Mixed on These Healthcare Stocks: BeiGene (ONC) and Omnicell (OMCL)

Why BeiGene, Ltd. (ONC) is Skyrocketing So Far in 2025

US$309 - That's What Analysts Think BeiGene, Ltd. (NASDAQ:ONC) Is Worth After These Results

Simply Wall St.

Is BeiGene, Ltd. (ONC) The Best Immunology Stock To Buy Now?

BeiGene granted orphan designation for sonrotoclax

BeOne Medicines Is Maintained at Outperform by Macquarie

BeOne Medicines Is Maintained at Market Outperform by Citizens Capital Markets

BeiGene (ONC) Receives a Buy from Morgan Stanley

BeiGene Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

BeiGene Faces Potential Tax Risks Amid Corporate Restructuring: Stakeholders Urged to Review SEC Filings

BUZZ-BeiGene Hong Kong shares hit over 3-year high as revenue jumps

Analysts Offer Insights on Healthcare Companies: BeiGene (ONC) and Viridian Therapeutics (VRDN)

Top Midday Gainers

MT Newswires Live

Stock Track | BeiGene Soars Over 6% as Q4 Results Beat Estimates, Upbeat 2025 Outlook, and Solid Pipeline Progress

BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/ONC/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ONC","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","market":"US","secType":"STK","nameCN":"BEIGENE LTD SPON ADS EACH REPR 13 ORD SHS","latestPrice":228.14,"timestamp":1744833600000,"preClose":238.84,"halted":0,"volume":575673,"hourTrading":{"tag":"盘后","latestPrice":228.14,"preClose":228.14,"latestTime":"17:22 EDT","volume":113476,"amount":25888029.956359997,"timestamp":1744838524891},"delay":0,"floatShares":79338939,"shares":107719405,"eps":-6.124009,"marketStatus":"Post-Mkt","change":-10.7,"latestTime":"04-16 18:21:41 EDT","open":235,"high":236.18,"low":227.69,"amount":132523188.66591,"amplitude":0.035547,"askPrice":240,"askSize":1,"bidPrice":225,"bidSize":4,"shortable":3,"etf":0,"ttmEps":-6.124009,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1744848000000},"marketStatusCode":4,"adr":0,"adrRate":13,"exchange":"NASDAQ","adjPreClose":238.84,"preHourTrading":{"tag":"盘前","latestPrice":239.87,"preClose":238.84,"latestTime":"07:58 EDT","volume":42,"amount":9929.07972,"timestamp":1744804700918},"postHourTrading":{"tag":"盘后","latestPrice":228.14,"preClose":228.14,"latestTime":"17:22 EDT","volume":113476,"amount":25888029.956359997,"timestamp":1744838524891},"volumeRatio":0.750043,"impliedVol":0.6114,"impliedVolPercentile":0.9306},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ONC\",,,,,undefined,":{"symbol":"ONC","floatShares":79338939,"roa":"-6.07%","roe":"-18.77%","lyrEps":-6.124009,"volumeRatio":0.750043,"shares":107719405,"dividePrice":0,"high":236.18,"amplitude":0.035547,"preClose":238.84,"low":227.69,"week52Low":126.9681,"pbRate":"7.37","psRate":"6.45","week52High":287.88,"institutionHeld":0,"latestPrice":228.14,"committee":0.6,"eps":-6.124009,"divideRate":0,"volume":575673,"delay":0,"ttmEps":-6.124009,"open":235,"prevYearClose":184.71,"prevWeekClose":230.36,"prevMonthClose":272.17,"prevQuarterClose":272.17,"fiveDayClose":206.32,"twentyDayClose":266.26,"sixtyDayClose":218.7,"earningDate":1747152000000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ONC\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2516622921","title":"TEVIMBRA Approved in U.S. for First-line Treatment of Advanced Esophageal Squamous Cell Carcinoma in Combination with Chemotherapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2516622921","media":"Business Wire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516622921?lang=en_us&edition=fundamental","pubTime":"2025-03-04 19:00","pubTimestamp":1741086000,"startTime":"0","endTime":"0","summary":"New indication based on results from a global Phase 3 trial demonstrating significantly improved overall survival benefit for PD-L1 positive patients treated with TEVIMBRA in combination with chemotherapy. SAN MATEO, Calif., March 04, 2025----BeiGene, Ltd. , a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration  has approved TEVIMBRA , in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma  whose tumors express PD-L1 (≥1).\"The approval of TEVIMBRA in combination with chemotherapy for adult patients with ESCC expands first-line treatment options for patients with this disease,\" said Dr. Nataliya Uboha, Associate Professor, University of Wisconsin, Carbone Cancer Center. \"There is a critical need for effective treatments of ESCC, and TEVIMBRA has been shown to improve outcomes in this patient population","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tevimbra-approved-u-first-line-110000996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0054578231.USD","BK4124","AEIS","OS","ONC","LU0053666078.USD","ITT","IE00B7SZL793.SGD","IE00B66KJ199.SGD","BK4097","BK4588","L","BK4157","BK4107","BK4585","BK4144","IE00B19Z4B17.USD","BK4161","TEN","IE0031619046.USD","BK4139","HSCT","LU0053671581.USD"],"gpt_icon":0},{"id":"2516801976","title":"BofA Securities Upgrades BeiGene to Buy, Price Target is $320","url":"https://stock-news.laohu8.com/highlight/detail?id=2516801976","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516801976?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:22","pubTimestamp":1741004524,"startTime":"0","endTime":"0","summary":"Onconetix Inc (ONCO) has an average rating of buy and mean price target of $316.11, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major bank","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["06160","ONC"],"gpt_icon":0},{"id":"2516680387","title":"Nomura Adjusts BeiGene Price Target to $347.02 From $316.65, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2516680387","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516680387?lang=en_us&edition=fundamental","pubTime":"2025-03-03 20:12","pubTimestamp":1741003926,"startTime":"0","endTime":"0","summary":"Nomura Adjusts BeiGene Price Target to $347.02 From $316.65, Maintains Buy Rating","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NMR","ONC","06160"],"gpt_icon":0},{"id":"2516613682","title":"Beigene Ltd : Bofa Global Research Raises to Buy From Neutral; Raises Price Objective to $320 From $207","url":"https://stock-news.laohu8.com/highlight/detail?id=2516613682","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516613682?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:37","pubTimestamp":1741001838,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250303:nFWN3PM0NM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["ONC","688235","BK0239","BK4139"],"gpt_icon":0},{"id":"2516682892","title":"BeiGene upgraded to Buy from Neutral at BofA","url":"https://stock-news.laohu8.com/highlight/detail?id=2516682892","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516682892?lang=en_us&edition=fundamental","pubTime":"2025-03-03 19:25","pubTimestamp":1741001155,"startTime":"0","endTime":"0","summary":"BofA analyst David Li upgraded BeiGene (ONC) to Buy from Neutral with a price target of $320, up from $207. The firm raised its revenue forecast fo...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beigene-upgraded-to-buy-from-neutral-at-bofa?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beigene-upgraded-to-buy-from-neutral-at-bofa?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ONC"],"gpt_icon":0},{"id":"2516689553","title":"Analysts’ Opinions Are Mixed on These Healthcare Stocks: BeiGene (ONC) and Omnicell (OMCL)","url":"https://stock-news.laohu8.com/highlight/detail?id=2516689553","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516689553?lang=en_us&edition=fundamental","pubTime":"2025-03-03 18:11","pubTimestamp":1740996665,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on BeiGene (ONC – Research Report) and Omnicell (OMCL...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-beigene-onc-and-omnicell-omcl?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-opinions-are-mixed-on-these-healthcare-stocks-beigene-onc-and-omnicell-omcl?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["OMCL","ONC","BK4167","HCSG","BK4082","BK4137","BK4139"],"gpt_icon":0},{"id":"2516524545","title":"Why BeiGene, Ltd. (ONC) is Skyrocketing So Far in 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2516524545","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516524545?lang=en_us&edition=fundamental","pubTime":"2025-03-03 00:52","pubTimestamp":1740934328,"startTime":"0","endTime":"0","summary":"We recently published an article titled Why These 15 Biotech Stocks Are Skyrocketing So Far In 2025.In this article, we are going to take a look at where BeiGene, Ltd.  stands against the other biotech stocks.No matter the market environment, you’ll always find entertainment in the biotech space. There will always be biotech stocks making huge swings in both directions and these stocks can make or break your portfolio in a very small amount of time due to the nature of how important clinical trial results are for these companies.The United Nations forecasts that the over-65 age group will grow by 150% from 800 million in 2024 to 2 billion by 2067. This \"older, richer & sicker\" population is expected to push global healthcare spending on medicines up 12% to $2.3 trillion by 2028. If you combine that with AI making breakthroughs in healthcare more frequent, you’ll see many more biotech stocks starting to pop to the upside over the coming years.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/why-beigene-ltd-onc-skyrocketing-165208264.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BEIGF","USAW.SI","NVIW.SI","QID","SQQQ","TSYW.SI","USJW.SI","MNQmain","PSQ",".IXIC","BK4139","TQQQ","QLD","NQmain","ONC"],"gpt_icon":1},{"id":"2516514249","title":"US$309 - That's What Analysts Think BeiGene, Ltd. (NASDAQ:ONC) Is Worth After These Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2516514249","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516514249?lang=en_us&edition=fundamental","pubTime":"2025-03-02 20:37","pubTimestamp":1740919039,"startTime":"0","endTime":"0","summary":"It's been a good week for BeiGene, Ltd.  shareholders, because the company has just released its latest yearly results, and the shares gained 6.4% to US$272. Revenues were a bright spot, with US$3.8b in revenue arriving 2.7% ahead of expectations, although statutory earnings didn't fare nearly so well, recording a loss of US$6.12, some 9.5% below consensus predictions. This is an important time for investors, as they can track a company's performance in its report, look at what experts are forecasting for next year, and see if there has been any change to expectations for the business. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.The most important thing to take away is that the analysts now expect BeiGene to become profitable next year, compared to previous expectations that it would report a loss. Happily, they also upgraded their revenue estimates, and ar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/us-309-thats-analysts-think-123719904.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SQQQ","QLD","ONC","NVIW.SI","LU2095319765.USD","USJW.SI","MNQmain","IE00B3QW5Z07.USD","BEIGF","NQmain","BK4588","TQQQ","BK4112","LU2210149790.SGD","BK4585","IE00B64PRP62.GBP","LU2210150020.SGD","TSYW.SI","NDAQ","BK4139","QID","IE00BKPKM429.USD","IE00BGHQF748.EUR","USAW.SI","PSQ",".IXIC"],"gpt_icon":1},{"id":"2516566882","title":"Is BeiGene, Ltd. (ONC) The Best Immunology Stock To Buy Now?","url":"https://stock-news.laohu8.com/highlight/detail?id=2516566882","media":"Insider Monkey","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516566882?lang=en_us&edition=fundamental","pubTime":"2025-03-02 03:42","pubTimestamp":1740858148,"startTime":"0","endTime":"0","summary":"We recently published a list of 10 Best Immunology Stocks To Buy Now. In this article, we are going to take a look at where BeiGene, Ltd.  stands against other best immunology stocks to buy now.Immunology is a rapidly advancing field with significant potential for growth, especially in the realm of biotech and pharmaceutical companies. As the global demand for innovative treatments for autoimmune diseases, cancer immunotherapies, and vaccines continues to rise, immunology stocks present lucrative investment opportunities. The market for immunotherapy medications is expected to rise at a high pace, from $240 billion in 2023 to $1.3 trillion in 2033. The rise in chronic illnesses like infections, autoimmune diseases, and various forms of cancer worldwide is what is causing the surge.In 2024, there will likely be more than 2 million new instances of cancer in the US, which will increase demand for efficient therapies like immunotherapy. To provide patients with incurable malignancies like","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-ltd-onc-best-immunology-194228024.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["MNQmain","QLD","NVIW.SI","USAW.SI","ONC","TSYW.SI","USJW.SI","SQQQ","BEIGF","NQmain","BK4139","QID","PSQ","TQQQ",".IXIC"],"gpt_icon":1},{"id":"2516063193","title":"BeiGene granted orphan designation for sonrotoclax","url":"https://stock-news.laohu8.com/highlight/detail?id=2516063193","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516063193?lang=en_us&edition=fundamental","pubTime":"2025-03-01 04:05","pubTimestamp":1740773147,"startTime":"0","endTime":"0","summary":"BeiGene’s (ONC) sonrotoclax was granted FDA orphan designation as a treatment of myelodysplastic syndromes, according to a post to the agency’s web...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/beigene-granted-orphan-designation-for-sonrotoclax?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/beigene-granted-orphan-designation-for-sonrotoclax?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","ONC"],"gpt_icon":0},{"id":"2516452372","title":"BeOne Medicines Is Maintained at Outperform by Macquarie","url":"https://stock-news.laohu8.com/highlight/detail?id=2516452372","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516452372?lang=en_us&edition=fundamental","pubTime":"2025-03-01 01:21","pubTimestamp":1740763260,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ONC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 28, 2025 12:21 ET (17:21 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","MDCO"],"gpt_icon":0},{"id":"2516379667","title":"BeOne Medicines Is Maintained at Market Outperform by Citizens Capital Markets","url":"https://stock-news.laohu8.com/highlight/detail?id=2516379667","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516379667?lang=en_us&edition=fundamental","pubTime":"2025-03-01 00:07","pubTimestamp":1740758820,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/ONC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  February 28, 2025 11:07 ET (16:07 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ONC","MDCO"],"gpt_icon":0},{"id":"2514322052","title":"BeiGene (ONC) Receives a Buy from Morgan Stanley","url":"https://stock-news.laohu8.com/highlight/detail?id=2514322052","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514322052?lang=en_us&edition=fundamental","pubTime":"2025-02-28 22:06","pubTimestamp":1740751597,"startTime":"0","endTime":"0","summary":"Morgan Stanley analyst Sean Laaman maintained a Buy rating on BeiGene (ONC – Research Report) today and set a price target of $317.00. The company’...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/beigene-onc-receives-a-buy-from-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/beigene-onc-receives-a-buy-from-morgan-stanley?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1720051017.SGD","LU0106831901.USD","LU2089284900.SGD","LU0225283273.USD","LU0320765646.SGD","BK4139","BK4581","LU2023251221.USD","LU0006306889.USD","BK4588","LU2111349929.HKD","BK4127","LU1989772840.SGD","LU2347655156.SGD","BK4504","IE00BZ1G4Q59.USD","LU1720051108.HKD","LU1668664300.SGD","LU1732799900.SGD","LU0971096721.USD","LU2028103732.USD","LU0158827948.USD","LU0912757837.SGD","BK4585","LU1363072403.SGD","LU1548497426.USD","LU0795875086.SGD","LU1162221912.USD","LU0158827781.USD","ONC","LU2089283258.USD","LU0098860793.USD","LU2133065610.SGD","IE00BKVL7J92.USD","LU0314104364.USD","LU0267386448.USD","LU0795875169.SGD","LU1074936037.SGD","LU0106261372.USD","LU1989772923.USD","LU1732800096.USD","LU2357305700.SGD","BK4534","LU2271345857.HKD","BK4516"],"gpt_icon":0},{"id":"2514190321","title":"BeiGene Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags","url":"https://stock-news.laohu8.com/highlight/detail?id=2514190321","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514190321?lang=en_us&edition=fundamental","pubTime":"2025-02-28 20:45","pubTimestamp":1740746738,"startTime":"0","endTime":"0","summary":"NasdaqGS:ONC Earnings and Revenue Growth February 28th 2025. All figures shown in the chart above are for the trailing 12 month  period. Revenue exceeded analyst estimates by 2.6%. Earnings per share  missed analyst estimates by 9.5%.Looking ahead, revenue is forecast to grow 15% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US.The company's shares are up 14% from a week ago.It's still necessary to consider the ever-present spectre of investment risk.   We've identified 1 warning sign  with BeiGene, and understanding this should be part of your investment process.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-full-2024-earnings-revenues-124538268.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ONC"],"gpt_icon":0},{"id":"2514394708","title":"BeiGene Faces Potential Tax Risks Amid Corporate Restructuring: Stakeholders Urged to Review SEC Filings","url":"https://stock-news.laohu8.com/highlight/detail?id=2514394708","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514394708?lang=en_us&edition=fundamental","pubTime":"2025-02-28 14:01","pubTimestamp":1740722517,"startTime":"0","endTime":"0","summary":"Beigene, Ltd. (ONC) has disclosed a new risk, in the Taxation & Government Incentives category. Beigene, Ltd. could be facing significant business ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/beigene-faces-potential-tax-risks-amid-corporate-restructuring-stakeholders-urged-to-review-sec-filings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/beigene-faces-potential-tax-risks-amid-corporate-restructuring-stakeholders-urged-to-review-sec-filings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["ONC","BK4139"],"gpt_icon":0},{"id":"2514616393","title":"BUZZ-BeiGene Hong Kong shares hit over 3-year high as revenue jumps","url":"https://stock-news.laohu8.com/highlight/detail?id=2514616393","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514616393?lang=en_us&edition=fundamental","pubTime":"2025-02-28 10:09","pubTimestamp":1740708545,"startTime":"0","endTime":"0","summary":"BUZZ-BeiGene Hong Kong shares hit over 3-year high as revenue jumps** Hong Kong shares of BeiGene Ltd 6160.HK jump 8.2% to HK$174.8, their highest since December 2021, and on course for fourth consecutive session of gains** Stock on track for the biggest one-day rise since February 21** Shanghai-listed stock 688235.SS surges 9.7% to record high at 248 yuan ** U.S. stock ONC.O jumped 7.5% on Thursday  ** Chinese oncology treatments developer said its total global revenues increased 78% y/y to $1.1 bln for Q4 and it was up 55% y/y to $3.8 bln for the full year of 2024 ** Full year 2025 revenue guidance of $4.9 bln to $5.3 bln - Co** Nomura, with \"Buy\" rating on the stock, says 4Q24 sales beat on balanced growth in the U.S., China, EU with higher FY25E sales guided ** Hang Seng Commerce & Industry Index .HSNC and healthcare index .HSCIH both fall 1.8%, Hang Seng Index .HSI eases 1.7%** Hong Kong-listed stock up 53.4% YTD, Shanghai shares up 50.6%, US shares up 50.7%  ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250228:nL2N3PJ01U:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06160","ONC","688235"],"gpt_icon":0},{"id":"2514135448","title":"Analysts Offer Insights on Healthcare Companies: BeiGene (ONC) and Viridian Therapeutics (VRDN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2514135448","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514135448?lang=en_us&edition=fundamental","pubTime":"2025-02-28 07:20","pubTimestamp":1740698406,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BeiGene (ONC – Research Report) and Viridian Therape...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-beigene-onc-and-viridian-therapeutics-vrdn?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-beigene-onc-and-viridian-therapeutics-vrdn?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCSG","VRDN","ONC","BK4137","BK4139"],"gpt_icon":0},{"id":"2514133980","title":"Top Midday Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2514133980","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514133980?lang=en_us&edition=fundamental","pubTime":"2025-02-28 02:48","pubTimestamp":1740682107,"startTime":"0","endTime":"0","summary":"Root  reported overnight Q4 sales that surged from a year ago, beating the average analyst estimate compiled by FactSet.Shares surged 29% as intraday trading volume soared to more than 1.96 million from a daily average of about 379,000.Mattel  and Warner Bros. Discovery's  Global Consumer Products division said Thursday they signed a multi-year global licensing agreement for DC stories and characters.Warner Bros. Q4 loss widened unexpectedly as sales slid more than forecast but it saw gains in subscribers on annual and sequential bases and forecast continuous growth for the metric.Shares of Warner Bros. jumped 12% as intraday trading volume climbed to more than 61.1 million from a daily average of about 28.5 million.BeiGene  shares jumped 8% after the company narrowed its Q4 net loss as revenue surged from a year ago.Shares advanced 8%, with intraday trading volume rising to over 748,000 from a daily average of about 414,000.Price: 128.58, Change: +29.87, Percent Change: +30.26","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BK4108","BK4551","BK4125","BK4588","ROOT","WBD","BK7104","BK7506","BK7507","BK4505","BK4585","ONC","BK4107","MAT","MAT.AU","BK4190"],"gpt_icon":0},{"id":"1191167492","title":"Stock Track | BeiGene Soars Over 6% as Q4 Results Beat Estimates, Upbeat 2025 Outlook, and Solid Pipeline Progress","url":"https://stock-news.laohu8.com/highlight/detail?id=1191167492","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1191167492?lang=en_us&edition=fundamental","pubTime":"2025-02-27 23:58","pubTimestamp":1740671921,"startTime":"0","endTime":"0","summary":"BeiGene Ltd  stock soared over 6% in pre-market trading on Thursday, February 27, 2025, following the company's strong financial performance in the fourth quarter and full year 2024, coupled with an upbeat revenue guidance for 2025 and promising updates on its solid tumor pipeline.The global oncology company reported better-than-expected revenue for Q4 2024, driven by robust sales growth of its flagship product BRUKINSA. Total revenue for the quarter stood at $1.13 billion, a 78% increase from t","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["ONC"],"gpt_icon":0},{"id":"2514382089","title":"BeiGene (ONC) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates","url":"https://stock-news.laohu8.com/highlight/detail?id=2514382089","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514382089?lang=en_us&edition=fundamental","pubTime":"2025-02-27 22:30","pubTimestamp":1740666627,"startTime":"0","endTime":"0","summary":"For the quarter ended December 2024, BeiGene, Ltd.  reported revenue of $1.13 billion, up 77.8% over the same period last year. EPS came in at -$1.43, compared to -$3.53 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $1.09 billion, representing a surprise of +3.76%. The company delivered an EPS surprise of -62.50%, with the consensus EPS estimate being -$0.88.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.Product revenue, net: $1.12 billion versus $1.08 billion estimated by four analysts on average. Compared to the year-ago quarter, this number represents a +77.3% ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/beigene-onc-q4-earnings-taking-143027178.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["ONC"],"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":2,"totalSize":61,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ONC\",params:#limit:5,,,undefined,":[{"date":"2025-05-14","symbol":"ONC","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":"2025/03","expectedEps":-0.74,"defaultRemindTime":1747209600000,"name":null,"time":"","dateTimestamp":1747195200000,"actualEps":null},{"market":"US","date":"2025-02-27","symbol":"ONC","fiscalQuarterEnding":"2024/12","expectedEps":-0.88,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1740632400000,"reportTimeType":"pre","actualEps":-1.43},{"market":"US","date":"2024-11-12","symbol":"ONC","fiscalQuarterEnding":"2024/09","expectedEps":-0.88,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-08-07","symbol":"ONC","fiscalQuarterEnding":"2024/06","expectedEps":-2.1,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723003200000,"reportTimeType":"pre","actualEps":-1.15},{"market":"US","date":"2024-05-11","symbol":"ONC","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1715400000000,"reportTimeType":"post","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ONC\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ONC\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2727,"buy":0.6818,"hold":0.0455,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6818,"analysts":22,"updateTime":1744084800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/ONC\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"ONC","date":"2025-04-15","current":-40.554363,"percent":0.362319,"low":-46.072488,"twenty":-42.82192,"median":-33.450565,"eighty":-28.752552,"high":-22.805663,"avg":-34.723533,"sd":7.392202,"marketCap":26148885563},"quantilePoints":[{"date":"2025-01-03","current":-23.85925,"twenty":-23.85925,"median":-23.85925,"eighty":-23.85925,"marketCap":19590153584},{"date":"2025-01-10","current":-23.169003,"twenty":-23.588216,"median":-23.51181,"eighty":-23.096335,"marketCap":18938568040},{"date":"2025-01-17","current":-26.770744,"twenty":-26.217794,"median":-23.689854,"eighty":-23.142836,"marketCap":21882666138},{"date":"2025-01-24","current":-28.798988,"twenty":-27.60701,"median":-25.13119,"eighty":-23.374687,"marketCap":23683664763},{"date":"2025-01-31","current":-29.253094,"twenty":-28.895055,"median":-26.770744,"eighty":-23.516999,"marketCap":24179205805},{"date":"2025-02-07","current":-29.699946,"twenty":-29.114029,"median":-28.456686,"eighty":-23.723733,"marketCap":24422582437},{"date":"2025-02-14","current":-29.279798,"twenty":-29.132261,"median":-28.781271,"eighty":-23.9826,"marketCap":24061904635},{"date":"2025-02-21","current":-31.546239,"twenty":-29.269116,"median":-28.798062,"eighty":-24.917918,"marketCap":26058437677},{"date":"2025-02-28","current":-46.072488,"twenty":-30.312806,"median":-28.916244,"eighty":-26.238043,"marketCap":29706894943},{"date":"2025-03-07","current":-42.702936,"twenty":-33.205878,"median":-29.060335,"eighty":-26.487572,"marketCap":27534255325},{"date":"2025-03-14","current":-42.304107,"twenty":-40.627279,"median":-29.228112,"eighty":-26.926934,"marketCap":27277096074},{"date":"2025-03-21","current":-43.63686,"twenty":-41.989697,"median":-29.279798,"eighty":-27.60701,"marketCap":28136436571},{"date":"2025-03-28","current":-43.795471,"twenty":-42.273573,"median":-29.808923,"eighty":-28.393975,"marketCap":28238706493},{"date":"2025-04-04","current":-44.082326,"twenty":-43.290212,"median":-30.877376,"eighty":-28.597906,"marketCap":28423666794},{"date":"2025-04-11","current":-34.741183,"twenty":-42.946887,"median":-33.164233,"eighty":-28.695114,"marketCap":22400628140},{"date":"2025-04-15","current":-40.554363,"twenty":-42.82192,"median":-33.450565,"eighty":-28.752552,"marketCap":26148885563}],"updateTime":1744800877384}}}